







Draft Genome Sequence of a *Pseudomonas aeruginosa* Sequence Type 3351 Strain Exhibiting High-Level Resistance to Polymyxins in a Pediatric Patient with Cystic Fibrosis in Mexico

 Roberto Rosales-Reyes,^{a,b} Fernanda Esposito,^{b,c} Bruna Fuga,^{c,d}  Louise Cerdeira,^d Catalina Gayosso-Vázquez,^a José L. Lezana-Fernández,^e Ricardo Lascurain,^f  Miguel A. Valvano,^g  Nilton Lincopan,^{b,c,d} José I. Santos-Preciado^{a,b}

^aUnidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico

^bIberoamerican Network for Combating Antimicrobial Resistance (INCAR)[‡]

^cDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil

^dDepartment of Microbiology, Institute of Biomedical Sciences, Universidade de São Paulo, São Paulo, Brazil

^eLaboratorio de Fisiología Pulmonar, Hospital Infantil de México Federico Gómez, Mexico City, Mexico

^fDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico

^gThe Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

Roberto Rosales-Reyes and Fernanda Esposito contributed equally to this work. Author order was determined by decreasing seniority.

ABSTRACT Here, we present the draft genome sequence of a *Pseudomonas aeruginosa* isolate (strain CF16053) belonging to a novel sequence type (ST), ST3351, isolated from a pediatric patient with cystic fibrosis (CF). CF16053 shows high-level resistance to polymyxins associated with mutations in the *pmrB* gene. Biofilm, pyoverdine, exotoxin A, and type III secretion system (T3SS) genes were identified.

Respiratory infections are the main cause of morbidity and mortality in patients with cystic fibrosis (CF), in whom *Pseudomonas aeruginosa* remains a leading pathogen (1, 2). Genomic investigation of antibiotic-resistant *P. aeruginosa* strains is essential for better understanding the molecular epidemiology and evolution of this pathogen, as well as for improving clinical outcomes in CF patients (3, 4). In this study, we report the draft genome sequence of a *P. aeruginosa* strain exhibiting high-level resistance to polymyxins in a pediatric patient with CF in Mexico.

P. aeruginosa strain CF16053 was isolated from a sputum culture from a 5-year-old male with CF. The sputum was inoculated onto MacConkey, chocolate, blood (Dibico), and ceftrimide (Becton, Dickinson) agar plates. Inoculated plates were incubated aerobically at 37°C for up to 48 h. Initial bacterial identification was performed using standard microbiological methods, and the species were confirmed with the API 20NE (bioMérieux SA) system. All samples were stored at –70°C until they were analyzed. Strain CF16053 was subcultured once before genomic analysis was performed. Identification and antibiotic susceptibility were determined by the Vitek 2 platform, whereas colistin and polymyxin B MICs were determined by microdilution following 2019 CLSI guidelines (5). The strain showed resistance to piperacillin-tazobactam (MIC > 128 µg/ml), colistin (MIC > 128 µg/ml), and polymyxin B (MIC > 128 µg/ml).

Total DNA from an isolated colony was extracted using the PureLink quick gel extraction kit (Life Technologies, CA). DNA quality and quantity were evaluated by agarose gel electrophoresis and by using a Qubit 2.0 fluorometer (Life Technologies). A genomic library was constructed using a Nextera DNA Flex library preparation kit, with subsequent sequencing by the MiSeq platform (300-bp paired-end reads; Illumina, Inc., San Diego, CA). The resistome and virulome were obtained using ResFinder version 3.2

Citation Rosales-Reyes R, Esposito F, Fuga B, Cerdeira L, Gayosso-Vázquez C, Lezana-Fernández JL, Lascurain R, Valvano MA, Lincopan N, Santos-Preciado JI. 2020. Draft genome sequence of a *Pseudomonas aeruginosa* sequence type 3351 strain exhibiting high-level resistance to polymyxins in a pediatric patient with cystic fibrosis in Mexico. Microbiol Resour Announc 9:e01261-19. <https://doi.org/10.1128/MRA.01261-19>.

Editor David A. Baltrus, University of Arizona

Copyright © 2020 Rosales-Reyes et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Roberto Rosales-Reyes, rrosales@ciencias.unam.mx, or Nilton Lincopan, lincopan@usp.br.

[‡]For this virtual institution, see <http://www.uui.unam.mx>.

Received 7 October 2019

Accepted 26 November 2019

Published 9 January 2020

(6), the Comprehensive Antibiotic Resistance Database (CARD) (7), and VFAnalyzer (8), respectively, whereas the multilocus sequence type (MLST) was predicted using MLST version 2.0 (9).

A total of 1,952,320 paired-end reads were generated with 94.46× coverage and *de novo* assembled into 52 contigs using SPAdes version 3.9.0 (10). Default parameters were used for all software unless otherwise specified. Quality filters were applied, and a Phred quality score of 20 was used. The sequence assembly was curated using Geneious version R9 (Biomatters Ltd., New Zealand) and submitted for annotation using NCBI Prokaryotic Genome Annotation Pipeline (PGAP) v.3.2 (11). The N_{50} value obtained was 425,394 bp. The genome size was calculated as 6,174,571 bp with a GC content of 66.4%, and the genome comprised 5,780 protein-coding sequences. In addition, 5,905 complete genes, 57 tRNAs, 3 rRNAs, 4 noncoding RNAs (ncRNAs), and 61 pseudogenes were identified.

The *P. aeruginosa* MLST database indicated a novel sequence type, where the different alleles of each gene were numbered *acsA17*, *aroE5*, *guaA11*, *mutL3*, *nuoD3*, *ppsA4*, and *trpE10*; it was therefore assigned to sequence type 3351 (ST3351) (12). Resistome analysis revealed that CF16053 harbored resistance genes to β -lactams (*bla*_{OXA-488} and *bla*_{P_{AO}}), phenicols (*catB7*), fosfomycin (*fosA*), and aminoglycosides [*aph*(3')-IIb]. Additionally, mutations in *pmrB* (T90A, H140Y, G211R, G213S, T215A, N250D, and V344A) and *pmrA* (L71A) genes that contribute to high-level polymyxins resistance (13, 14) were also identified.

Virulome analysis identified genes related to biofilm formation (quorum sensing genes *lasA* and *ptxR*) and genes associated with alginate synthesis (*algG*, *algI*, *alg8*, *algE*, *algA*, *algX*, *algK*, *algF*, *algD*, *algJ*, *alg44*, *algL*, and *algB*). Furthermore, siderophore pyoverdine synthesis (*pvdA*, *pvdD*, *pvdE*, *pvdF*, *pvdG*, *pvdL*, *pvdN*, *pvdO*, *pvdQ*, *pvdP*, and *pvdS*), exotoxin A (*toxA*), and type III secretion system (T3SS) (*exoS* and *exoT*) genes were also identified.

In summary, we report for the first time the draft genome sequence of a novel ST3351 (determined by MLST) *P. aeruginosa* strain displaying high-level resistance to polymyxins that was obtained from a child with CF in Mexico. These data could contribute to a better understanding of acquired resistance in *P. aeruginosa* lineages infecting people with CF.

Data availability. The genome sequence of *Pseudomonas aeruginosa* strain CF16053 has been deposited in GenBank under accession number [VTFM00000000](https://www.ncbi.nlm.nih.gov/nuccore/VTFM00000000) (SRA accession number [PRJNA562177](https://www.ncbi.nlm.nih.gov/nuccore/PRJNA562177)).

ACKNOWLEDGMENTS

We thank Martha J. Arredondo-Mercado for her help with the manuscript editing.

This work was supported by the Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (grant number PAPIIT IN224491), Conselho Nacional de Desenvolvimento Científico e Tecnológico (grant numbers AMR 443819/2018-1 and 433128/2018-6 and fellowship number 312249/2017-9), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (grant numbers 88887.358057/2019-00 and 1794306). N.L. is a research fellow of CNPq (fellowship number 312249/2017-9). F.E. is a research fellow of FAPESP (fellowship number 2019/15578-4).

REFERENCES

- Malhotra S, Hayes D, Wozniak DJ. 2019. Cystic fibrosis and *Pseudomonas aeruginosa*: the host-microbe interface. *Clin Microbiol Rev* 32:e00138-18. <https://doi.org/10.1128/CMR.00138-18>.
- Parkins MD, Somayaji R, Waters VJ. 2018. Epidemiology, biology, and impact of clonal *Pseudomonas aeruginosa* infections in cystic fibrosis. *Clin Microbiol Rev* 31:e00019-18. <https://doi.org/10.1128/CMR.00019-18>.
- Ramanathan B, Jindal HM, Le CF, Gudimella R, Anwar A, Razali R, Poole-Johnson J, Manikam R, Sekaran SD. 2017. Next generation sequencing reveals the antibiotic resistant variants in the genome of *Pseudomonas aeruginosa*. *PLoS One* 12:e0182524. <https://doi.org/10.1371/journal.pone.0182524>.
- Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z. 2019. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol Adv* 37:177-192. <https://doi.org/10.1016/j.biotechadv.2018.11.013>.
- CLSI. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. CLSI supplement M100. CLSI, Wayne, PA.
- Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial

- resistance genes. *J Antimicrob Chemother* 67:2640–2644. <https://doi.org/10.1093/jac/dks261>.
7. Jia B, Raphenya AR, Alcock B, Waglehner N, Guo P, Tsang KK, Lago BA, Dave BM, Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE, Frye JG, Elsayegh T, Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FSL, Wright GD, McArthur AG. 2017. CARD 2017: expansion and model-centric curation of the Comprehensive Antibiotic Resistance Database. *Nucleic Acids Res* 45:D566–D573. <https://doi.org/10.1093/nar/gkw1004>.
 8. Liu B, Zheng D, Jin Q, Chen L, Yang J. 2019. VFDB 2019: a comparative pathogenomic platform with an interactive Web interface. *Nucleic Acids Res* 47:D687–D692. <https://doi.org/10.1093/nar/gky1080>.
 9. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Pontén T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol* 50:1355–1361. <https://doi.org/10.1128/JCM.06094-11>.
 10. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshtkin AV, Sirotkin AV, Yahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19:455–477. <https://doi.org/10.1089/cmb.2012.0021>.
 11. Tatusova T, DiCuccio M, Badretdin A, Chetverin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI Prokaryotic Genome Annotation Pipeline. *Nucleic Acids Res* 44: 6614–6624. <https://doi.org/10.1093/nar/gkw569>.
 12. Jolley KA, Bray JE, Maiden M. 2018. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open Res* 3:124. <https://doi.org/10.12688/wellcomeopenres.14826.1>.
 13. Olaitan AO, Morand S, Rolain J-M. 2014. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 5:643. <https://doi.org/10.3389/fmicb.2014.00643>.
 14. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Høiby N. 2012. PmrB mutations promote polymyxin resistance of *Pseudomonas aeruginosa* isolated from colistin-treated cystic fibrosis patients. *Antimicrob Agents Chemother* 56:1019–1030. <https://doi.org/10.1128/AAC.05829-11>.